| Literature DB >> 34008277 |
Yuta Kobayashi1,2, Takaaki Masuda1, Atsushi Fujii1, Dai Shimizu1, Kuniaki Sato1, Akihiro Kitagawa1,2, Taro Tobo3, Yuki Ozato1,2, Hideyuki Saito1, Shotaro Kuramitsu1, Miwa Noda1, Hajime Otsu1, Tsunekazu Mizushima2, Yuichiro Doki2, Hidetoshi Eguchi2, Masaki Mori4, Koshi Mimori1.
Abstract
Microtubules are among the most successful targets for anticancer therapy because they play important roles in cell proliferation as they constitute the mitotic spindle, which is critical for chromosome segregation during mitosis. Hence, identifying new therapeutic targets encoding proteins that regulate microtubule assembly and function specifically in cancer cells is critical. In the present study, we identified a candidate gene that promotes tumor progression, ribonucleic acid export 1 (RAE1), a mitotic checkpoint regulator, on chromosome 20q through a bioinformatics approach using datasets of colorectal cancer (CRC) including The Cancer Genome Atlas (TCGA). RAE1 was ubiquitously amplified and overexpressed in tumor cells. High expression of RAE1 in tumor tissues was positively associated with distant metastasis and was an independent poor prognostic factor in CRC. In vitro and in vivo analysis showed that RAE1 promoted tumor growth, inhibited apoptosis and promoted cell cycle progression, possibly with a decreased proportion of multipolar spindle cells in CRC. Furthermore, RAE1 induced chemoresistance by its anti-apoptotic effect. In addition, overexpression of RAE1 and significant effects on survival were observed in various types of cancer, including CRC. In conclusion, we have identified RAE1 as a novel gene that facilitates tumor growth in part by inhibiting apoptosis and promoting cell cycle progression by stabilizing spindle bipolarity and facilitating tumor growth. We suggest that it is a potential therapeutic target to overcome therapeutic resistance of CRC. This article is protected by copyright. All rights reserved.Entities:
Keywords: Ribonucleic Acid Export 1 (RAE1); colorectal cancer; heterogeneity; mitosis; tumor growth
Year: 2021 PMID: 34008277 DOI: 10.1111/cas.14969
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716